GlassScriptPhysician profile
Venkatram Rajaram
NPI 1154359768
$20,096.19
in general payments reported to CMS, 2019-2025
39 companies · $7,687 in 2025
The $7,687 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $1,054 · 2021: $2,340 · 2022: $1,040 · 2023: $890 · 2024: $5,428 · 2025: $7,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $7,383 · Food and Beverage: $4,644 · Travel and Lodging: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $7,383.33 |
| Food and Beverage | $4,643.56 |
| Travel and Lodging | $1,977.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $7,545.92 | 2022-2025 | Auryon Laser System 100-120 Vac, Alphavac |
| Abbott Laboratories | $3,949.86 | 2019-2025 | Aveir, Gallant, Tendril |
| Medtronic, INC. | $3,155.85 | 2021-2025 | Micra, Hawkone, Selectsecure |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,055.87 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $934.48 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $619.29 | 2019-2025 | Avvigo Guidance System, Accolade Sr |
| Astrazeneca Pharmaceuticals LP | $379.52 | 2021-2024 | Farxiga |
| Pfizer INC. | $309.87 | 2019-2025 | |
| Abiomed | $212.43 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $188.46 | 2019-2025 | Rotarexs 6 F X 135 Cm, Venclose Maven Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.88 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $165.60 | 2021-2025 | |
| Esperion Therapeutics, INC. | $142.63 | 2020-2021 | |
| Chiesi USA, INC. | $135.18 | 2019-2022 | |
| Cardiovascular Systems INC. | $97.52 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.40 | 2022 | |
| Impulse Dynamics (USA) INC. | $89.81 | 2022-2024 | Optimizer, Optimizer |
| Asahi Intecc USA, INC. | $85.62 | 2020-2024 | Peripheral Vascular |
| E.R. Squibb & Sons, L.L.C. | $79.39 | 2020-2024 | Eliquis, Camzyos |
| Inari Medical, INC. | $77.54 | 2020-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic Vascular, INC. | $63.33 | 2019 | |
| Novo Nordisk INC | $62.79 | 2020-2025 | Wegovy, Ozempic |
| W. L. Gore & Associates, INC. | $58.62 | 2024-2025 | Gore Viabahn Vbx Balloon Expandable Endo |
| Cook Medical LLC | $43.71 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $43.01 | 2024-2025 | Assure Wcd |
| Becton, Dickinson and Company | $37.05 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $36.49 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $33.00 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $31.00 | 2023 | Onpattro |
| Amgen INC. | $30.75 | 2021 | |
| Tactile Systems Technology INC | $24.08 | 2025 | Flexitouch Plus, Nimbl |
| Cvrx, INC. | $20.81 | 2024 | Barostim Neo System |
| Smith+Nephew, INC. | $18.41 | 2022 | |
| Glaxosmithkline, LLC. | $17.92 | 2025 | Shingrix |
| Cardiva Medical, INC. | $17.65 | 2025 | Cardiva Vascade 5f Vcs |
| Kiniksa Pharmaceuticals International, Plc | $16.71 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $15.68 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $15.45 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkatram Rajaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.